Prior Therapy, Genomics, and Patient Factors in mCRPC Treatment Selection
Treatment selection for patients with metastatic castration-resistant prostate cancer (mCRPC) remains complex, requiring a personalized approach that integrates genomic testing, prior therapy history, and patient-specific factors, according to Dr. Kristine Lacuna of Memorial Sloan Kettering Cancer Center. Speaking at the 2026 Annual American Urology Association Meeting, Dr. Lacuna emphasized that there is no single “right” answer for sequencing treatments, necessitating a multidisciplinary strategy to improve patient outcomes.
Navigating Treatment Selection in mCRPC
Selecting therapy for mCRPC depends heavily on whether a patient has previously received androgen receptor pathway inhibitors (ARPI). According to Dr. Lacuna, patients fall into two primary categories: those who have already undergone ARPI therapy and those who remain ARPI-naive. For patients who have not yet received an ARPI, the PEACE-3 study indicates that combining enzalutamide with radium-223 offers a significant overall survival advantage and improved radiographic progression-free survival in patients with bone metastases.
For patients who have already progressed on an ARPI, genomic testing is essential to guide subsequent choices. Dr. Lacuna notes that if patients exhibit HRR alterations, such as BRCA2 mutations, utilizing genomically driven therapies early provides a clear clinical benefit, as demonstrated in the PROfound and TRITON-3 studies. In cases where patients do not have these specific mutations, clinicians may consider options such as chemotherapy with docetaxel or lutetium-177 (PSMA-617), depending on the individual’s prior treatment history and clinical profile.
Approximately 5% of the mCRPC patient population presents with MSI-high or TMB-high tumors, which may allow for the use of targeted immunotherapy like pembrolizumab, though the optimal timing for this intervention remains an area of active clinical consideration.
The Role of Bone-Modifying Agents
Preventing skeletal-related events (SREs), such as fractures, is a critical goal in the management of mCRPC, yet data from the Flatiron database suggests these agents are underutilized. Dr. Lacuna advises that bone-modifying agents like Zometa or Denosumab should be used routinely in all mCRPC patients to protect quality of life and prevent outcomes that can lead to hospice care. These treatments are particularly vital when using regimens like the PEACE-3 protocol, and they should be paired with consistent calcium and vitamin D supplementation.
The shift toward biomarker-driven oncology highlights a transition away from “one-size-fits-all” protocols. By prioritizing genomic sequencing and addressing bone health early, clinicians are attempting to mitigate the risks of aggressive disease progression, even when optimal sequencing data remains limited.
Future Considerations in Clinical Practice
As the field moves forward, the primary challenge remains the lack of clear data on optimal sequencing of advanced therapies. While trials like PR.21 have compared treatments such as docetaxel and lutetium-177, they have not identified a definitive superior sequence, suggesting that clinical decisions will continue to rely on the specific needs and toxicities presented by each patient. Future developments could see a greater reliance on multidisciplinary teams—including radiation oncologists and medical oncologists—to coordinate metastasis-directed therapy for patients with limited disease progression or specific molecular profiles.
Frequently Asked Questions
Is there a standard sequence for using docetaxel versus lutetium-177?
According to Dr. Lacuna, there is no established optimal sequence. The PR.21 trial showed no significant difference in progression-free survival between the two, though docetaxel was associated with higher toxicity. The choice typically depends on the individual patient’s clinical situation and PSMA avidity.
Should bone-modifying agents be used for all mCRPC patients?
Yes. Dr. Lacuna emphasizes that these agents should be used routinely in every patient with mCRPC to prevent fractures and other skeletal-related events, which significantly impact patient survival and quality of life.
How do genomic factors influence treatment?
Genomic testing is vital for identifying patients with HRR or BRCA-related alterations. These patients may benefit from specific targeted therapies, such as PARP inhibitors, which have shown clear benefits in patients previously treated with an ARPI.
How do you think increased access to genomic testing will change the way your community approaches long-term cancer care?